Blockade of CXCL12/CXCR4 Axis Ameliorates Murine Experimental Colitis
Open Access
- 20 August 2008
- journal article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in Journal of Pharmacology and Experimental Therapeutics
- Vol. 327 (2), 383-392
- https://doi.org/10.1124/jpet.108.141085
Abstract
Recent studies indicate that the CXCL12/CXCR4 interaction is involved in several inflammatory conditions. However, it is unclear whether this interaction has a role in the pathophysiology of inflammatory bowel disease (IBD). We investigated the significance of this interaction in patients with IBD and in mice with dextran sulfate sodium (DSS)-induced colitis and the effect of a CXCR4 antagonist on experimental colitis. First, we measured CXCR4 expression on peripheral T cells in patients with IBD. Furthermore, we investigated CXCR4 expression on leukocytes and CXCL12 expression in the colonic tissue of mice with DSS-induced colitis, and we evaluated the effects of a CXCR4 antagonist on DSS-induced colitis and colonic inflammation of interleukin (IL)-10 knockout (KO) mice. Colonic inflammation was assessed both clinically and histologically. Cytokine production from mesenteric lymph node cells was also examined. CXCR4 expression on peripheral T cells was significantly higher in patients with active ulcerative colitis (UC) compared with normal controls, and CXCR4 expression levels of UC patients correlated with disease activity. Both CXCR4 expression on leukocytes and CXCL12 expression in colonic tissue were significantly increased in mice with DSS-induced colitis. Administration of a CXCR4 antagonist ameliorated colonic inflammation in DSS-induced colitis and IL-10 KO mice. CXCR4 antagonist reduced tumor necrosis factor-α and interferon-γ production from mesenteric lymph node cells, whereas it did not affect IL-10 production. The percentage of mesenteric Foxp3+CD25+ T cells in DSS-induced colitis was not affected by CXCR4 antagonist. These results suggest that blockade of this chemokine axis might have potential as a therapeutic target for the treatment of IBD.Keywords
This publication has 37 references indexed in Scilit:
- Local production of chemokines and prostaglandin E2 in the acute, chronic and recovery phase of murine experimental colitisCytokine, 2006
- Chemokine receptor expression in rat adjuvant‐induced arthritisArthritis & Rheumatism, 2005
- Regulated production of the chemokine CCL28 in human colon epitheliumAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2004
- Identification of a CXCR4 antagonist, a T140 analog, as an anti‐rheumatoid arthritis agentFEBS Letters, 2004
- Induction of the chemokine stromal-derived factor-1 following DNA damage improves human stem cell functionJCI Insight, 2000
- The chemokine SDF-1 stimulates integrin-mediated arrest of CD34+ cells on vascular endothelium under shear flowJCI Insight, 1999
- Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar developmentNature, 1998
- The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tractNature, 1998
- The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entryNature, 1996
- Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1Nature, 1996